TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Replimune Group, Inc.
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Replimune presented biomarker data showing RP1 plus nivolumab can potentially reverse resistance mechanisms to PD-1 blockade in advanced melanoma, demonstrating a 33.6% response rate and 24.8-month median response duration.

Insights
XOM   positive

42-year dividend increase streak, investing in low-production regions, 3.4% dividend yield


REPL   positive

Presented promising clinical trial results showing potential breakthrough in melanoma treatment, with positive data on reversing resistance mechanisms